EyePoint Pharmaceuticals (EYPT) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Citi Opens 30-Day Upside Catalyst Watch on EyePoint Inc. (EYPT)
May 6, 2026 4:08 PM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $35.00 price target on EyePoint Inc. (NASDAQ: EYPT)
Opens 30-Day upside catalyst watch.For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.
Shares of EyePoint Inc. closed at $13.75 yesterday.
... More